Article

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.

Department of Psychiatry, Mental Health Unit, Queen Elizabeth II Hospital, Howlands, Hertfordshire, Welwyn Garden City, UK.
International Clinical Psychopharmacology (Impact Factor: 3.1). 07/2005; 20(4):223-6. DOI: 10.1097/00004850-200507000-00005
Source: PubMed

ABSTRACT This study aimed to determine the efficacy and tolerability of adding quetiapine to a serotonin reuptake inhibitor in treatment-resistant obsessive-compulsive disorder (OCD). Twenty-one adult treatment-resistant OCD patients were randomized to 16 weeks of augmentation with either quetiapine (n = 11) or placebo (n = 10). Patients with significant comorbidities, including tic-spectrum disorders, were not included. The treatment was well tolerated, with only one premature dropout in each treatment-group. The primary analysis showed that individuals in the quetiapine-treated group showed a 14% mean improvement in baseline Yale-Brown Obsessive-Compulsive Scale scores at study endpoint compared with a 6% improvement in those treated with placebo, but this difference did not reach statistical significance (F<1). Three patients treated with quetiapine met criteria for clinical response, compared to one patient who was treated with placebo. Larger studies are needed to explore the efficacy of second generation antipsychotics, such as quetiapine, when used as adjunct treatment in resistant OCD.

0 Bookmarks
 · 
74 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background In 2006, the National Institute of Clinical and Health Excellence (NICE) guidelines for Obsessive Compulsive Disorder (OCD) recommended anti-psychotics as a class for SSRI treatment resistant OCD. The article aims to systematically review and conduct a meta-analysis on the clinical effectiveness of atypical anti-psychotics augmenting an SSRI.Methods Studies that were double-blind randomized controlled trials of an atypical antipsychotic against a placebo, for a minimum of 4 weeks, in adults with OCD, were included. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. Inclusion criteria included Y-BOCS score of 16 or more and at least one adequate trial of a SSRI or clomipramine for at least 8 weeks prior to randomization. Data sources included Medline, Embase, PsycINFO, Cochrane Database of Systematic Reviews (CDSR), trial registries and pharmaceutical databases and manufacturers up to September 2013. Forest-plots were drawn to display differences between drug and placebo on the Y-BOCS.ResultsTwo studies found aripiprazole to be effective in the short-term. There was a small effect-size for risperidone or anti-psychotics in general in the short-term. We found no evidence for the effectiveness of quetiapine or olanzapine in comparison to placebo.Conclusions Risperidone and aripiprazole can be used cautiously at a low dose as an augmentation agent in non-responders to SSRIs and CBT but should be monitored at 4 weeks to determine efficacy.
    BMC Psychiatry 11/2014; 14(1):317. · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Los antipsicóticos atípicos se utilizan de manera creciente en el tratamiento de los trastornos de ansiedad, ya sea en monoterapia o como tratamiento combinado. Esta es la primera revisión en la que se presenta el uso de los antipsicóticos atípicos en monoterapia o como potenciación en pacientes con trastornos de ansiedad primarios o con (trastornos) de ansiedad correspondientes a una comorbilidad de la esquizofrenia, el trastorno bipolar (TBP) o el trastorno depresivo mayor (TDM). Incluimos en la revisión un total de 49 ensayos de diseño abierto, 32 ensayos aleatorizados y controlados con placebo (EACpl) y 5 ensayos aleatorizados y controlados sin un grupo placebo, con casi 6.000 pacientes (diseño abierto: 1.710, aleatorizados: 4.145). Un número creciente de EACpl muestran resultados prometedores en un 27-71% de los pacientes con trastornos de ansiedad primarios o comórbidos tratados con antipsicóticos atípicos en monoterapia o con un tratamiento de potenciación. Sin embargo, las deficiencias metodológicas de los estudios incluidos pueden limitar las conclusiones de esta revisión y está justificada la realización de ensayos controlados con placebo más amplios para comparar el tratamiento estándar en monoterapia o de potenciación con antipsicóticos atípicos frente al de placebo. Además, las tasas de abandono del tratamiento más elevadas y los efectos secundarios del empleo de antipsicóticos atípicos pueden limitar el uso de estos fármacos en pacientes con trastornos de ansiedad.
    Psiquiatría Biológica. 12/2012; 19:21-41.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objetivo e Método: Apesar de existirem terapêuticas eficazes para o tratamento do transtorno obsessivo-compulsivo, uma parcela significativa dos pacientes acometidos por tal condição não alcança ou não mantém a remissão dos sintomas mesmo com tratamento adequado. O alívio do sofrimento destes pacientes com os tratamentos existentes representa um desafio para o clínico, que, nestas situações, se vê, freqüentemente, sem respostas satisfatórias. O objetivo desta revisão da literatura é avaliar os conceitos e critérios de resistência e refratariedade ao tratamento, abordar os aspectos intrínsecos e extrínsecos à fenomenologia descritiva do transtorno obsessivo-compulsivo que possam influenciar a resposta aos tratamentos convencionais preconizados, e propor um fluxo de alternativas terapêuticas para casos resistentes e refratários às diversas abordagens. Conclusão: A literatura evidencia que tanto aspectos intrínsecos à fenomenologia do transtorno obsessivo-compulsivo, quanto aspectos extrínsecos po-dem colaborar para que pelo menos 30% dos pacientes não obtenham o resultado desejado. Várias alternativas de tratamento e/ ou de potencialização, sejam psicofarmacológicas, biológicas ou psicoterápicas, estão disponíveis, mas vários estudos ainda são necessários para que as evidências apontem na direção mais adequada para a remissão dos sintomas. A b s t r a c t Objective and Method: Despite the existence of effective therapeutic alternatives for obsessive-compulsive disorder, a significant number of patients does not achieve or does not maintain remission after adequate treatment. The relief of these patients' suffering with the available treatments is a clinical challenge related to many unanswered questions. The objective of this literature review is to evaluate the current concepts of treatment resistance and refractoriness, to describe the intrinsic and extrinsic factors of obsessive-compulsive disorder's phenomenology that might influence treatment response to conventional treatment, and to present a fluxogram of therapeutic alternatives for resistant or refractory obsessive compulsive disorder patients. Conclusion: The literature evinces that intrinsic and/or extrinsic phenomenological aspects of obsessive-compulsive disorder may collaborate to the fact that, at least 30% of obsessive-compulsive disorder patients do not respond to conventional treatment. Several therapeutic or augmentation alternatives, psychopharmacological, biological or even psychotherapeutical exists, but more studies are necessary to evince the correct way to symptom remission.